Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07718620 | HPV-associated Oropharyngeal Carcinoma (HPV-OPC)(HPV-OPC) | recruiting | N/A | 35 | Masaryk Memorial Cancer InstituteOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04722523 | A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer | recruiting | Phase 1 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07241273 | SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer(SELECT-FR) | not yet recruiting | N/A | 128 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04852328 | Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma | recruiting | Phase 2 | 30 | Washington University School of MedicineOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07059221 | A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer | recruiting | Phase 1 / Phase 2 | 210 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07532928 | A Bidirectional Study of Individualized Postoperative Adjuvant Treatment Decision Model for Locally Advanced Head and Neck Squamous Cell Carcinoma Based on Multimodal Dynamic Data | enrolling by invitation | — | 571 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT00707473 | Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer | terminated | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04375384 | Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer | recruiting | Phase 2 | 38 | Wake Forest University Health SciencesOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05115760 | Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement Rate in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation Therapy | active not recruiting | N/A | 57 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05522985 | Toripalimab-based Neoadjuvant Therapy in LA-HNSCC | active not recruiting | Phase 2 | 122 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06788990 | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC(FORTIFI-HN01) | recruiting | Phase 2 / Phase 3 | 650 | Bicara TherapeuticsINDUSTRY | 26 | Jul 17, 2026 | clinicaltrials |
| NCT07398664 | H101 Plus TACE for r/m HNSCC | recruiting | Phase 2 | 20 | West China HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03565783 | Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery | active not recruiting | Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03690986 | VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer | active not recruiting | Phase 1 | 35 | Emory UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03892993 | Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers | recruiting | N/A | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04874493 | Patient Reported Outcome Post Radiation Therapy or Chemoradiotherapy Patient Care in Patients With Oropharyngeal Cancer | active not recruiting | — | 77 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05075980 | Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study | active not recruiting | Phase 2 | 174 | Mayo ClinicOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06662058 | Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation | recruiting | N/A | 118 | Emory UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07064902 | Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07665190 | Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma(RESERVE-HC) | recruiting | Phase 2 | 52 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07706985 | Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 566 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT01365169 | Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" | recruiting | N/A | 590 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT05799144 | pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer | recruiting | Phase 2 | 54 | Michael K. GibsonOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06307093 | Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms | completed | Phase 1 | 90 | R-PharmINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06997094 | Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer | recruiting | Phase 1 | 32 | Mayo ClinicOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07521670 | Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)(STRAP) | not yet recruiting | Phase 2 | 68 | National Cancer Centre, SingaporeOTHER | 4 | Jul 15, 2026 | clinicaltrials |
| NCT07662720 | A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer(MORALE-HN01) | not yet recruiting | Phase 1 / Phase 2 | 18 | Glycyx TherapeuticsINDUSTRY | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07705243 | Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 3 | 86 | Sun Yat-sen UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02474368 | Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck | active not recruiting | Phase 1 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT03712566 | Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy(MASST) | active not recruiting | — | 39 | University Health Network, TorontoOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07302672 | Humanistic Continuing Care Via WeChat for Patients Undergoing Thermal Ablation of Papillary Thyroid Carcinoma | recruiting | N/A | 108 | Ming-an YuOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07435324 | A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma | completed | Phase 3 | 161 | R-PharmINDUSTRY | 2 | Jul 14, 2026 | clinicaltrials |
| NCT04858269 | First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients | active not recruiting | Phase 2 | 31 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03942653 | Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma | active not recruiting | Phase 2 | 20 | Manish PatelOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05813626 | Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 89 | Zhejiang Cancer HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07695974 | Clinicopathological Predictors of Recurrence in Papillary Thyroid Carcinoma | completed | — | 1,113 | University of Roma La SapienzaOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07586124 | Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 80 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07601737 | Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 182 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07692360 | Salivary IL-6 and Interleukin Gene Polymorphisms in Oral Squamous Cell Carcinoma(IL6-OSCC) | not yet recruiting | — | 38 | University of PaviaOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07692906 | Multimodal Evaluation-Guided Surveillance-Intervention With Endoscopic Selective Neck Dissection for Post-Radiotherapy N3 Nasopharyngeal Carcinoma | not yet recruiting | N/A | 80 | Xuelei Ma MDOTHER | 0 | Jul 9, 2026 | clinicaltrials |
| NCT04291105 | Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | active not recruiting | Phase 2 | 87 | Vyriad, Inc.INDUSTRY | 2 | Jul 8, 2026 | clinicaltrials |
| NCT06797986 | A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. | recruiting | Phase 1 / Phase 2 | 37 | Cellid Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07545837 | Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors | recruiting | N/A | 20 | Mayo ClinicOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07567235 | Clinical Study of CFH Protein Via Ice Microneedles for Radiation-Induced Skin Fibrosis | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07578467 | Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs | not yet recruiting | Phase 1 / Phase 2 | 35 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT07578727 | A Multicenter, Prospective, Phase III Clinical Study of Proton Intensity-modulated Radiotherapy Versus Photon Intensity-modulated Radiotherapy for Untreated Non-metastatic Nasopharyngeal Carcinoma | not yet recruiting | N/A | 504 | Guangzhou Concord Cancer CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03085056 | Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer | active not recruiting | Early Phase 1 | 13 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05751486 | A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma | completed | Phase 1 | 64 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 7, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 22, 2026source: clinicaltrials